Immune checkpoint inhibitors (ICIs) have become a widely adopted cancer therapy since the FDA’s approval of the first anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody in 2011. The gene discussed is CTLA4; the disease is cancer.